Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 5/20 | 0.44 |
| ▸ | ATIC | P31939 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 5/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MGAT2 | Q10469 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MGAT3 | Q09327 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086082 | 1.00 | MOGAT2 (0.44) | MOGAT2ATICLMNAACLYSLC22A12 | |
| SCHEMBL31085749 | 0.96 | ATIC (0.46) | MOGAT2ATICLMNAACLYSLC22A12 | |
| SCHEMBL31086172 | 0.92 | ATIC (0.44) | MOGAT2ATICLMNAACLYSLC22A12 | |
| SCHEMBL31085907 | 0.91 | ATIC (0.43) | MOGAT2ATICLMNAACLYSLC22A12 | |
| SCHEMBL31086074 | 0.91 | CRBN (0.42) | MOGAT2ATICLMNAACLYSLC22A12 | |
| SCHEMBL24697648 | 0.89 | ATIC (0.41) | MOGAT2ATICACLYCRBNKMT2A | |
| SCHEMBL31086076 | 0.89 | ATIC (0.41) | MOGAT2ATICACLYCRBNKMT2A | |
| SCHEMBL24697651 | 0.89 | ACLY (0.45) | ATICLMNAACLYSLC22A12CRBN | |
| SCHEMBL31085776 | 0.89 | ACLY (0.45) | ATICLMNAACLYSLC22A12CRBN | |
| SCHEMBL31086063 | 0.89 | ATIC (0.44) | MOGAT2ATICLMNAACLYSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |